Form 4: Allogene Therapeutics Executive Acquires Shares and Stock Options

Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics, acquired shares and stock options on March 1, 2025.

Summary

• On March 1, 2025, Benjamin Machinas Beneski, the SVP and Chief Technical Officer of Allogene Therapeutics, acquired 31,755 shares of common stock at $0.
• Following the transaction, Beneski directly owns 223,995 shares of Allogene Therapeutics.
• Beneski also acquired stock options for 112,339 shares with an exercise price of $1.80, expiring on March 1, 2035.
• 25% of these options vest on March 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares and options could be seen as a slightly positive signal, but it's not definitive.

Positives

• The acquisition of shares and stock options by a high-ranking executive could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.

Key Dates